Sofpironium bromide

Drug Profile

Sofpironium bromide

Alternative Names: BBI-4000

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bodor Laboratory
  • Developer Brickell Biotech; Kaken Pharmaceutical
  • Class Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperhidrosis

Most Recent Events

  • 01 Dec 2016 Brickell Biotech initiates a phase II trial in Hyperhidrosis in USA (NCT03024255)
  • 01 Aug 2016 Brickell Biotech completes a phase II trial for Hyperhidrosis in USA (NCT02682238)
  • 05 Mar 2016 Efficacy and adverse events data from a phase II trial in Hyperhidrosis, which met its primary endpoint, presented at the 74th Annual Meeting of the American Academy of Dermatology (AAD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top